Changes in Hong Kong stocks | Intosilicon Intelligence (03696) rose more than 5% in the afternoon, and the company and international team revealed new targets and early biomarkers of Alzheimer's disease

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Insili Intelligence (03696) rose more than 5% in the afternoon. As of press release, it had risen 5.53% to HK$46.16, with a turnover of HK$304 million.

According to the news, Insilicon Smart announced that a landmark study has been published in “Alzheimer's Disease and Dementia: Alzheimer's Association Journal”. The study involved researchers from the University of Oslo (UiO) and Akershus University Hospital (Ahus), and was led by Dr. Sofie Lautrup and Professor Evandro Fei Fang. The research team discovered novel molecular targets for Alzheimer's disease (AD) and other neurodegenerative diseases using Pandaomics, an AI biology platform independently developed by Insilis Intelligence and combined with extensive experimental verification.

Notably, Ren Feng, Co-CEO and Chief Scientific Officer of Intosilicon Intelligence, recently said in an interview with the Securities Times that the company currently has 10 pipelines in clinical development. Among them, phase III clinical trials of the idiopathic pulmonary fibrosis project have already started in China. Once successful, it may be a “DeepSeek moment” in the field of AI pharmaceuticals.